NEW YORK, Sept. 19 – Bayer and Millennium Pharmaceuticals said Wednesday they had extended their alliance to look for new drug targets to battle thrombosis, urinary incontinence, and benign prostatic hypertrophy. 

The companies, which began working together in 1998 and have until now focused on cardiovascular diseased, cancer, pain, hematology, and viral infections, said they have so far identified more than 140 potential drug targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.